447 related articles for article (PubMed ID: 35306339)
41. Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease.
He L; Liu F; Yan W; Huang M; Huang M; Xie L; Guo Y; Xu X; Chu C; Wu L; Liang X; Sun S; Wang F; Zhao L; Zhao Q; Ma X; Xie L; Huang G
Pediatr Int; 2021 Jul; 63(7):757-763. PubMed ID: 33600060
[TBL] [Abstract][Full Text] [Related]
42. Predictive value of monocyte to HDL-C ratio for coronary artery lesions and intravenous immunoglobulin resistance in Kawasaki disease.
Wang JR; Zhao HZ; Chang LJ; Xu X; Gao Y; Li M; Kong QY; Wang MM; Zhao CF
Eur J Pediatr; 2023 Oct; 182(10):4399-4406. PubMed ID: 37480545
[TBL] [Abstract][Full Text] [Related]
43. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
[TBL] [Abstract][Full Text] [Related]
44. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
45. Role of glucocorticoids in Kawasaki disease.
Miura M
Int J Rheum Dis; 2018 Jan; 21(1):70-75. PubMed ID: 29105310
[TBL] [Abstract][Full Text] [Related]
46. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.
Burns JC; Best BM; Mejias A; Mahony L; Fixler DE; Jafri HS; Melish ME; Jackson MA; Asmar BI; Lang DJ; Connor JD; Capparelli EV; Keen ML; Mamun K; Keenan GF; Ramilo O
J Pediatr; 2008 Dec; 153(6):833-8. PubMed ID: 18672254
[TBL] [Abstract][Full Text] [Related]
47. Kawasaki disease: 40 years after the original report.
Gedalia A
Curr Rheumatol Rep; 2007 Aug; 9(4):336-41. PubMed ID: 17688844
[TBL] [Abstract][Full Text] [Related]
48. [Clinical analysis of 942 cases of Kawasaki disease].
Zhang W; Li Q; Zhao XD; Tang XM; Wang XG; Wang M; Wu DQ; Ou Q; Yang XQ
Zhonghua Er Ke Za Zhi; 2006 May; 44(5):324-8. PubMed ID: 16780705
[TBL] [Abstract][Full Text] [Related]
49. Kawasaki disease in Sicily: clinical description and markers of disease severity.
Maggio MC; Corsello G; Prinzi E; Cimaz R
Ital J Pediatr; 2016 Nov; 42(1):92. PubMed ID: 27806720
[TBL] [Abstract][Full Text] [Related]
50. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.
Xue LJ; Wu R; Du GL; Xu Y; Yuan KY; Feng ZC; Pan YL; Hu GY
Clin Rev Allergy Immunol; 2017 Jun; 52(3):389-400. PubMed ID: 27550227
[TBL] [Abstract][Full Text] [Related]
51. Epidemiologic study of Kawasaki disease and cases resistant to IVIG therapy in Thailand.
Durongpisitkul K; Sangtawesin C; Khongphatthanayopthin A; Panamonta M; Sopontammarak S; Sittiwangkul R; Pongpanich B
Asian Pac J Allergy Immunol; 2006 Mar; 24(1):27-32. PubMed ID: 16913186
[TBL] [Abstract][Full Text] [Related]
52. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome.
Saulsbury FT
Clin Pediatr (Phila); 2002 Oct; 41(8):597-601. PubMed ID: 12403377
[TBL] [Abstract][Full Text] [Related]
53. Aspirin Dose in Kawasaki Disease: The Ongoing Battle.
Dhanrajani A; Chan M; Pau S; Ellsworth J; Petty R; Guzman J
Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1536-1540. PubMed ID: 29287309
[TBL] [Abstract][Full Text] [Related]
54. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
Wang X; Pan SL; DU ZH; Ji ZX; Luo G; Sun HX; Ma SJ
Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):399-404. PubMed ID: 35527415
[TBL] [Abstract][Full Text] [Related]
55. Kawasaki Disease: Beyond IVIG and Aspirin.
Moussa T; Wagner-Weiner L
Pediatr Ann; 2019 Oct; 48(10):e400-e405. PubMed ID: 31609999
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study.
Takura T; Horiuchi S
J Cardiol; 2022 Aug; 80(2):172-178. PubMed ID: 35341683
[TBL] [Abstract][Full Text] [Related]
57. Infliximab treatment for refractory COVID-19-associated multisystem inflammatory syndrome in a Japanese child.
Yamaguchi Y; Takasawa K; Irabu H; Hiratoko K; Ichigi Y; Hirata K; Tamura Y; Murakoshi M; Yamashita M; Nakatani H; Shimoda M; Ishii T; Udagawa T; Shimizu M; Kanegane H; Morio T
J Infect Chemother; 2022 Jun; 28(6):814-818. PubMed ID: 35125343
[TBL] [Abstract][Full Text] [Related]
58. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
Takekoshi N; Kitano N; Takeuchi T; Suenaga T; Kakimoto N; Suzuki T; Kada TT; Shibuta S; Tachibana S; Murayama Y; Yamaga H; Suzuki H
JAMA Netw Open; 2022 Jun; 5(6):e2216642. PubMed ID: 35696166
[TBL] [Abstract][Full Text] [Related]
59. Importance of C-reactive protein level in predicting non-response to additional intravenous immunoglobulin treatment in children with Kawasaki disease: a retrospective study.
Iwashima S; Kimura M; Ishikawa T; Ohzeki T
Clin Drug Investig; 2011; 31(3):191-9. PubMed ID: 21456105
[TBL] [Abstract][Full Text] [Related]
60. Kawasaki disease: Medical therapies.
Newburger JW
Congenit Heart Dis; 2017 Sep; 12(5):641-643. PubMed ID: 28580631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
